

Caregiver Support on Tablo Home Hemodialysis

Cynthia J. D'Alessandri-Silva¹, Christopher Gunter¹, Michael A. Aragon¹, David E. Henner²
 1. Outset Medical, San Jose, CA 2. Berkshire Medical, Pittsfield, MA

BACKGROUND / INTRODUCTION




- The treatment of End-Stage Renal Disease (ESRD) at home can significantly impact daily activities and health-related quality of life (QOL) for patients.
- With home hemodialysis (HHD), care partners often share in the physical, mental, and social burden of self-care at home.
- Understanding and quantifying that burden provides opportunity to create technology and develop resources to better support patients and families performing home hemodialysis.

METHODS

- The HOME Registry Study (NCT04526301) is an ongoing multi-center, prospective, single-arm study investigating clinical and QOL outcomes on patients receiving HHD with the Tablo® Hemodialysis System (Tablo).
- In this interim analysis, the following were analyzed to quantify the impact of Tablo training on the care partner's perception of readiness and QOL once home assisting with treatment.
 - Care Partner-Net Promotor Score (NPS)
 - Care Partner-Post Training Questionnaire
 - Zarit Burden Interview (ZBI)

RESULTS

- Ninety-nine participants were enrolled into the HOME Registry Study, mean age 57, 73% male, 78% non-Hispanic/Latino, with 70% married or in a domestic relationship, and 50 care partners reporting at baseline.
- Of care partner responses after completing training, 96% agree or strongly agree with “being satisfied with Tablo training received”, 98% agree or strongly agree they are “confident in supporting my partner’s dialysis treatment with Tablo System”, and 100% of care partners agree or strongly agree with being “satisfied with what is being asked of them as a care partner”
- At month 12, 100% of responses reported: Sometimes, Rarely, or Never “feeling stressed between caring for their relative and meeting my own responsibilities” and to “feeling that I've lost control of my life since my relatives' sickness”.
- In addition, 89% reported: Sometimes, Rarely, or Never “feeling I don't have enough time for myself due to my relative's HHD”.
- Mean care partner NPS at month 12, reported on a 10-point scale from 1 “not at all likely” to 10 “extremely likely”, was 8.94 at month-6 and 8.90 at month-12.



DISCUSSION / CONCLUSION

- Care partners surveyed in the HOME Registry study report confidence in their training.
- Care partners report confidence in their ability to care for their loved one with little impact on their own QOL.
- In addition, based on their experience, care partners of patients on Tablo at home were very likely to recommend Tablo HHD to others.



Important Safety Information
Tablo Indication Statement
 The Tablo® Hemodialysis System and TabloCart™ is indicated for use in patients with acute and/or chronic renal failure, with or without ultrafiltration, in an acute or chronic care facility. Treatment must be administered under physician's prescription and observed by a trained individual who is considered competent in the use of the device. The Tablo Hemodialysis System is also indicated for use in the home. Treatment types available include Intermittent Hemodialysis (IHD), Sustained Low Efficiency Dialysis (SLED), SLEDD, Prolonged Intermittent Renal Replacement Therapy (PIRRT), and Isolated Ultrafiltration. This device is not indicated for continuous renal replacement therapy (CRRT) and is cleared for use for up to 24 hours. The dialysate generated by this device is not sterile and should not be used for intravenous (IV) infusion.